NOVEL VANILLOID RECEPTOR LIGANDS AND USE THEREOF IN PRODUCING MEDICINAL AGENTS Russian patent published in 2013 - IPC C07D213/64 C07D213/70 C07D213/74 A61K31/44 A61K31/4545 A61P25/00 

FIELD: chemistry.

SUBSTANCE: invention relates to substituted compounds of general formula I , in which n equals 1; R¹ denotes H; F; Cl; Br or I; R² denotes H; F; Cl; Br; I; -CF₃; -CN; -NH₂; -OH or -OR¹⁶; R³ denotes H; F; Cl; Br; I; -NH₂; -NO₂; -OH; -C(=O)-NH₂; -C(=NH)-NH₂; -NH-C(=O)-R¹³; -OR¹⁶; -C(=O)-NHR¹⁸; -C(=O)-R²⁵ or a linear or branched, saturated of unsaturated, unsubstituted or at least mono-substituted aliphatic C_1-10 radical, where said substitutes are independently selected from a group which includes F; -OH; -NH₂; -NH(C_1-5-alkyl) and -N(C_1-5-alkyl)(C_1-5-alkyl); R⁴ denotes H; F; Cl; Br, I or a linear or branched, saturated or unsaturated, unsubstituted aliphatic C_1-10 radical; R⁵ denotes H; F; Cl; Br or I; R⁶ denotes H or a linear or branched, saturated or unsaturated, unsubstituted aliphatic C_1-10 radical; R⁷ denotes hydrogen; R⁸ denotes -CF₃; -O-CFH₂; -O-CF₂H; -CFH₂; -CF₂H or an unsubstituted or at least mono-substituted tert-butyl radical; T denotes C-R³⁵; U denotes C-R³⁶; V denotes N or C-R³⁷; W denotes C-R³⁸ and where values of R13, R16, R18, R25, R35, R36, R37 and R38 are as given in claim 1 of the invention. The invention also relates to methods of producing the compounds described above, a medicinal compound based on said compounds for treating vanilloid receptor mediated disorders or diseases, as well as use of compounds of formula I to produce a medicinal agent.

EFFECT: novel compounds used as vanilloid receptor ligands are obtained and described.

25 cl, 34 ex, 1 tbl